Compartir
Microbiome in 3p Medicine Strategies: The First Exploitation Guide (en Inglés)
Boyko, Nadiya ; Golubnitschaja, Olga (Autor)
·
Springer
· Tapa Dura
Microbiome in 3p Medicine Strategies: The First Exploitation Guide (en Inglés) - Boyko, Nadiya ; Golubnitschaja, Olga
$ 3,098.84
$ 6,197.68
Ahorras: $ 3,098.84
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Reino Unido
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Martes 04 de Junio y el
Viernes 14 de Junio.
Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.
Reseña del libro "Microbiome in 3p Medicine Strategies: The First Exploitation Guide (en Inglés)"
The book analyses microbiome-relevant findings focused on clinical needs providing the roadmap to implement recent achievements in the area representing a valuable contribution to the paradigm shift from reactive to predictive, preventive and personalised medicine (PPPM / 3PM) considered as the most advanced concept in medicine. Already well-acknowledged as well as future advantages of application of pre-, pro- and pharma-biotics are detailed in the book. Socio-economic impacts of the area are considered in the context of the entire spectrum of healthcare services from disease care provided to patients up to health care provided to persons in suboptimal health conditions. Innovative technologies including phenotyping, genotyping, individualised profiling, patient stratification, big data analysis, and multi-omics, amongst others are all involved in the book. The book is unique from view point of multi-professional expertise involved. International network presents more than 10 countries worldwide including Belgium, China, Germany, Israel, Ukraine and USA. The data presented are of great scientific value and of particular importance for educating a broad spectrum of professionals including researchers, healthcare givers, policy makers, business people, policy makers and general population.
